Oligonucleotide composition, kit and method for detecting allopurinol medication anaphylaxis and application

Through HLA-B*5801 allelic detection and DNA enzyme catalytic technology, the problem of allopurinol drug allergic reaction detection is solved, high sensitivity and specific detection of severe skin allergic reactions is achieved, and the safety of drug use is improved .

CN118910245AInactive Publication Date: 2024-11-08HUBEI MEDICINE IND RES INST CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411129874.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-16
Publication Date
2024-11-08
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The prior art lacks effective methods to detect allopurinol allergic reactions, especially severe skin allergic reactions, which leads to clinical inability to prevent and deal with them in advance, affecting the safe use of the drug by patients.

Method used

By designing oligonucleotide compositions and kits, using HLA-B*5801 allelic detection, combined with DNAse catalysis and colorimetric molecular beacon technology, high sensitivity and specific detection of allergic reactions to allopurinol drugs can be achieved. .

Benefits of technology

It provides a simple, accurate and low-cost method that can effectively prevent and detect severe skin allergic reactions caused by allopurinol medication. It is suitable for Asian people and improves the safety of drug use.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118910245A_ABST
    Figure CN118910245A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of allopurinol medication anaphylaxis, in particular to an oligonucleotide composition, a kit, a method and application for detecting allopurinol medication anaphylaxis. The composition comprises a molecular beacon 1, a molecular beacon 2 and a sequence 6. The kit comprises the composition, ABTS and hydrogen peroxide. The allele of HLA-B * 5801 is amplified through the oligonucleotide composition for detection, so that the serious skin adverse reaction caused by allopurinol medication is detected or prevented. The method has the characteristics of simplicity in operation, high sensitivity, specificity and accuracy and low cost.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of allopurinol allergic reactions, and in particular to an oligonucleotide composition, a kit, a method and uses for detecting allergic reactions to allopurinol. Background Art

[0002] Drug hypersensitivity is a serious adverse drug reaction. In clinical practice, oral drug hypersensitivity reactions often can only be treated based on the patient's hypersensitivity reaction due to the lack of a suitable measurement method. The prevalence of hyperuricemia (HUA) has been increasing year by year, becoming the second largest metabolic disease after diabetes. Allopurinol is a xanthine oxidase inhibitor that can block uric acid synthesis in the body. It is a conventional drug for clinical uric acid lowering treatment with significant efficacy. With its widespread clinical use, the adverse drug reactions of allopurinol, especially severe skin allergic reactions, have gradually attracted attention. Studies have found that severe cutaneous adverse reactions (SCAR) caused by allopurinol treatment in the Han population are strongly correlated with carrying the HLA-B*5801 allele (Wu R, Cheng YJ, Zhu LL, et al. Impact of HLA-B*5801 allele and allopurinol-induced cutaneous adverse drug reactions: evidence from 21 pharmacogenetic studies [J]. Oncotarget, 2016, 7 (49): 81870-81879."). As early as 2012, the American College of Rheumatology recommended that Asian people undergo HLA-B*5801 gene testing before using allopurinol when conditions permit, and those with positive results should avoid using allopurinol. Therefore, the use of HLA-B*5801 allele testing to determine whether a subject has adverse drug reactions to allopurinol has obvious application prospects. Summary of the invention

[0003] The present invention provides an oligonucleotide composition, a kit, a detection method and uses for detecting allergic reactions to allopurinol. By detecting the HLA-B*5801 allele, it is possible to detect whether a subject has an adverse drug reaction to allopurinol, and the method has the characteristics of high detection sensitivity and specificity. The detection method is simple and easy to use, and is suitable for clinical detection of allergic reactions to allopurinol.

[0004] One of the purposes of the present invention is to provide an oligonucleotide composition for detecting allergic reactions to allopurinol. The composition comprises:

[0005] Molecular Beacon 1:

[0006] 5'-HEM-NH2-C6-TCCTAAGAACGGACCCCTGAA A AATCTTTACGTCTTAGGA-C6-NH2-HEM-3', with amino groups at both ends, and the italicized part is the stem part of molecular beacon 1;

[0007] Molecular Beacon 2:

[0008] 5'-HEM-NH2-C6-TCCTAAGAACGGACCCCTGAA C AATCTTTACGTCTTAGGA-C6-NH2-HEM-3', with amino groups at both ends, and the italicized part is the stem part of molecular beacon 2;

[0009] Sequence 6: 5'-GGGGTGGGTAGGGGTGGGTAGGGGTTGG-3'.

[0010] One of the purposes of the present invention is to provide a kit for detecting allergic reactions to allopurinol, which includes the oligonucleotide composition.

[0011] Furthermore, the kit also includes:

[0012] F:GCATCAGCATTGCCTGGGGACTTT;

[0013] Fm: GCATCAGCATTGCCTGGGGACTTG

[0014] R: AAGTATTTCCTGGAGGACTTGGG.

[0015] Specifically, the kit includes independently packaged 40-150 nM molecular beacon 1 solution, 40-150 nM molecular beacon 2 solution, 50-200 nM sequence 6 solution, 1-2 mM ABTS solution and 1-2 mM hydrogen peroxide solution.

[0016] Specifically, the kit further includes independently packaged 10-50 nM F solution, 10-50 nM Fm solution and 10-50 nM R solution.

[0017] One of the purposes of the present invention is to provide a method for detecting allergic reactions to allopurinol. The method comprises: reacting the DNA of a sample to be tested with molecular beacon 1 or molecular beacon 2 to obtain a hybridization solution; mixing the hybridization solution with a sequence 6 solution to form a DNA enzyme solution; adding an ABTS solution and a hydrogen peroxide solution to the DNA enzyme solution, and detecting the ultraviolet absorption value at 420 nm.

[0018] Specifically, the method comprises:

[0019] A solution containing 40 nM molecular beacon 1 or molecular beacon 2 and 20 nM DNA of the sample to be tested was prepared with Tris-HCl solution, heated in a water bath at 85°C for 5 min, cooled to room temperature for 30 min, and reacted in a water bath for 65 min;

[0020] A 160 nM solution of sequence 6 was prepared in TE buffer, heated in a 90°C water bath for 10 min, and then annealed in an ice bath for 10 min to prevent sequence 6 from self-aggregation and convert it into a straight chain;

[0021] Take 100 μL of the hybridization solution and the mixture of equal volumes of sequence 6 solution, add 200 μL 2×HEPES, 90 μL porphyrin iron culture solution, 5 μL KCL solution and 5 μL DMSO, shake evenly and transfer to a 30°C water bath shaker in the dark for 60 minutes to form a DNase solution;

[0022] Take 1mL of DNA enzyme solution and place it in a 1cm optical path quartz cuvette, add 15μL of 1.46mM ABTS solution and mix well as the base solution, scan the baseline to subtract the background signal, then add 9μL of 1.22mM hydrogen peroxide solution, mix well, and detect the ultraviolet absorption value at 420nm.

[0023] Furthermore, the method also includes firstly performing PCR amplification on the DNA of the sample to be tested, then reacting the PCR amplification product with the molecular beacon to obtain a hybridization solution, and performing subsequent detection reaction steps. The amplification system is (20 μL): 2 μL DNA of the sample to be tested, 0.4 μL F or Fm, 0.4 μL R, 0.4 μL P, 4 μL 5× buffer, 2 μL 10× buffer, 2 μL dNTP, 0.2 μL DNA polymerase and the remainder of double distilled water. The amplification procedure is: preheating stage: 50°C 2min, 95°C 10min; reaction stage (40 cycles): 95°C 15sec; 60°C 35sec.

[0024] One of the purposes of the present invention is to provide the use of the oligonucleotide composition and the kit in preparing a reagent for detecting an allergic reaction to the use of allopurinol.

[0025] Beneficial effects of the present invention:

[0026] The present invention provides a method for detecting genotypes associated with severe skin allergic reactions to anti-hyperuricemia allopurinol drugs. The method has high specificity and is designed to amplify the alleles of HLA-B*5801 for detection by an oligonucleotide composition, thereby detecting or preventing the occurrence of severe skin adverse reactions to allopurinol. The present invention has the characteristics of simple operation, high sensitivity, specificity and accuracy, and low cost. It is suitable for Chinese and Asian patients to confirm whether anti-hyperuricemia drugs such as allopurinol can be used by detecting the HLA-B*5801 gene before taking anti-hyperuricemia drugs such as allopurinol. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 HPLC charts of molecular beacon 2 and porphyrin iron-modified molecular beacon 2.

[0028] Figure 2 When the molecular beacon 1 is used to detect sequence 1, an obvious ultraviolet absorption curve can be formed.

[0029] Figure 3 When using molecular beacon 2 to detect sequence 2, an obvious ultraviolet absorption curve can be formed.

[0030] Figure 4 The absorbance at 420 nm is the absorbance of sequence 1 detected by molecular beacon 1 and sequence 2 detected by molecular beacon 2.

[0031] Figure 5 In order to use the molecular beacon 2 to detect sequence 2 of different concentrations, an obvious ultraviolet absorption curve can be formed.

[0032] Figure 6 The absorbance values ​​at 420 nm of sequence 2 of different concentrations were detected using molecular beacon 2.

[0033] Figure 7 for Figure 6 The fitting curve of .

[0034] Figure 8 The results are specific for molecular beacon detection.

[0035] Fig. 9 The electrophoresis diagrams are of the amplification products of sequence 1, sequence 2, clinical positive samples and clinical negative samples amplified using the F / R and Fm / R primer pairs, respectively.

[0036] Fig.10 The absorbance values ​​at 420 nm of positive samples and clinical negative samples are detected by using F / R primer pairs, Fm / R primer pairs, molecular beacons and combinations thereof. DETAILED DESCRIPTION

[0037] In order to make the purpose, technical scheme and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the examples. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention. The reagents not described separately in detail in the present invention are all conventional reagents and can be obtained from commercial channels; the methods not described in detail are all conventional experimental methods and can be obtained from the prior art.

[0038] 1. Nucleic acid composition

[0039]

[0040] The 5' and 3' ends of the molecular beacon are modified with amino groups. The italicized sequence is a stem-like site that can be paired with each other, and the italicized middle sequence is a site that can form a ring. Sequence 1 is a sequence that is completely complementary to the molecular beacon, and the underlined site is chr6:31880443:T. Sequence 2 is a sequence that is completely complementary to the molecular beacon, and the underlined site is the mutation site chr6:31880443:G. Sequence 3 is a two-mismatched sequence of sequence 1, and the underlined site is the mutation site chr6:31880443:T, and the underlined and bolded sites are the mismatched sites at both ends of the mutation site. Sequence 4 is a two-mismatched sequence of sequence 2, and the underlined site is the mutation site chr6:31880443:G, and the underlined and bolded sites are the mismatched sites at both ends of the mutation site. Sequence 5 is a random sequence. Sequence 6 is a G-rich nucleotide sequence that can form a G-tetrad DNAzyme with porphyrin iron.

[0041] The present invention constructs a method for detecting severe skin allergic reactions due to allopurinol medication by constructing a method based on DNA enzyme catalysis and specific recognition and hybridization of colorimetric molecular beacons and fully complementary oligonucleotides. The stem and tail ends of the synthesized porphyrin iron modified molecular beacon are double-labeled with porphyrin iron (HEM) having electrochemical activity and catalytic activity. The colorimetric beacon with DNA enzyme catalytic activity can be used to detect sequences containing chr6:31880443 mutation sites. When there is no target, the porphyrin iron modified molecular beacon exists in a stem-loop structure and cannot produce a DNA enzyme with catalytic activity, so that almost no catalytic signal is generated under this condition. When there is a target sequence, the porphyrin iron modified molecular beacon hybridizes and complements with the target DNA, and the porphyrin iron at the stem tail end is separated to destroy the stem-loop structure, forming a DNA enzyme with horseradish peroxidase activity. The DNA enzyme can catalyze hydrogen peroxide to oxidize ABTS into green ABTS+, and then the concentration of the target sequence can be distinguished by the change of color.

[0042] 2. Preparation of porphyrin iron modified molecular beacons

[0043] Under nitrogen atmosphere, porphyrin iron, DDC (dicyclohexylcarbodiimide) and NHS (N-hydroxysuccinimide) were added to DMF solvent in a molar ratio of 1:2:3, and the reaction was carried out in the dark for 30 minutes to obtain a solution containing porphyrin iron ester. After the reaction was completed, the solution was precipitated with 10 times the volume of isopropanol for 10 minutes. After the porphyrin iron ester was precipitated, it was centrifuged at 12000 rpm for 3 minutes, and the precipitate was collected, which was porphyrin iron ester, and dried with nitrogen.

[0044] Dissolve the molecular beacon in 10mM sodium carbonate solution (pH=8.5) to prepare the molecular beacon solution. Before the molecular beacon solution reacts, place it in a 90℃ water bath for 10min and then anneal it in an ice bath for 10min to promote its unzipping. Add the molecular beacon solution to 90μL of DMF solution containing porphyrin iron ester at a molar ratio of 2.5:1 (porphyrin iron ester: molecular beacon), mix thoroughly, add 0.25 molar ratio of catalyst DIPEA (N,N-diisopropylethylamine), shake thoroughly, seal, and react in a 40℃ constant temperature water bath oscillator for 4h in the dark. Add 2.5 times the volume of anhydrous frozen ethanol solution and 0.1 times the volume of 3M NaCL solution to the reaction solution, seal and shake evenly, freeze at -20℃ for 30min, take out, and centrifuge at 12000rpm for 12min. The insoluble matter was removed from the lower layer, and redissolved with 100 μL 10 mM sodium carbonate solution (pH = 7.5), and then washed and frozen twice by adding 2.5 volumes of anhydrous frozen ethanol solution and 0.1 volumes of 3M NaCL solution. Finally, it was dissolved with 100 μL 10 mM sodium carbonate solution (pH = 7.5) to obtain a preliminarily purified porphyrin iron modified molecular beacon mixture for later use.

[0045] The preliminarily purified porphyrin iron modified molecular beacon mixture was loaded into Lh-20 dextran gel packing, and after balancing the column for 2 hours, it was eluted with 10mM sodium carbonate solution (pH=7.5), and the elution peak with an absorbance value greater than 0.1 under ultraviolet at 398nm was collected, ultrafiltration and concentration, freeze-dried, and dissolved with 10mM sodium carbonate solution (pH=7.5). The column, ultrafiltration, washing, and freezing processes were repeated repeatedly. After the impurities were completely removed by ultraviolet analysis, ultrafiltration and concentration were performed, and freeze-dried to obtain a purified light yellow solid, which was the porphyrin iron modified molecular beacon.

[0046] HPLC detection: Instruments used: Waters 1525; Binary HPLC Pump Waters 2487; DualλAbsorbance Detector. Column: Agilent TC-C18(2) 5μm 4.6×150mm. UV absorption wavelength set at 260nm. Eluent used: A is 0.1M triethylamine acetate, B is anhydrous acetonitrile. Gradient elution: 0→35min, 95%A→5%A. Results are shown in Figure 1 As shown, the light yellow solid obtained by the above steps is mainly porphyrin iron modified molecular beacon 2 (18.3 min), almost does not contain molecular beacon 2 (6 min), but contains a small amount of porphyrin iron (22.5 min).

[0047] 3. Detection using molecular beacon 1 or molecular beacon 2

[0048] (1) Testing process

[0049] Molecular beacon 1 was used to detect sequence 1 and sequence 3, respectively, and molecular beacon 2 was used to detect sequence 2 and sequence 4, respectively.

[0050] A solution containing 40 nM molecular beacon 1 and 20 nM target DNA (sequence 1) was prepared with Tris-HCl solution, heated in a water bath at 85°C for 5 min, cooled to room temperature for 30 min, and reacted in a water bath for 65 min.

[0051] A 160 nM solution of sequence 6 was prepared with TE buffer, heated in a 90°C water bath for 10 min, and then annealed in an ice bath for 10 min to prevent sequence 6 from self-aggregation and convert it into a straight chain.

[0052] Take 100 μL of a mixture of equal volumes of hybridization solution and sequence 6 solution, add 200 μL 2×HEPES, 90 μL porphyrin iron culture medium (containing 25 mM HEPES, 200 mM sodium chloride, 20 mM potassium chloride, pH 8.0), 5 μL KCL solution and 5 μL DMSO, oscillate evenly and transfer to a 30°C water bath oscillator in the dark for reaction for 60 minutes to form DNA enzyme, and sequence 1 can be detected by colorimetry.

[0053] Take 1mL of the above-formed DNA enzyme solution and place it in a 1cm optical path quartz cuvette, add 15μLABTS (3-ethylbenzothiazole-6-sulfonic acid) solution (C=1.46mM) and mix well as the base solution, scan the baseline to deduct the background signal, then add 9μL of hydrogen peroxide solution (C=1.22mM), mix well, and then measure its ultraviolet kinetic absorption curve. The wavelength range is 300-500nm, the scanning speed is 1200nm / s, and the ultraviolet scanning detection is 10min.

[0054] (2) Test results

[0055] like Figure 2 As shown in FIG. 1 , the detection of sequence 1 by molecular beacon 1 can form an obvious ultraviolet absorption curve with an absorption peak at 420 nm. The detection of sequence 3 by molecular beacon 1 does not have an obvious ultraviolet absorption curve and absorption peak. Figure 4 It can be seen that the absorbance value of sequence 1 detected by molecular beacon 1 at 420 nm is significantly higher than that of sequence 3.

[0056] like Figure 3 As shown in FIG. 1 , the use of molecular beacon 2 to detect sequence 2 can form an obvious ultraviolet absorption curve with an absorption peak at 420 nm. The use of molecular beacon 2 to detect sequence 4 does not have an obvious ultraviolet absorption curve and absorption peak. Figure 4 It can be seen that the absorbance value of sequence 2 detected by molecular beacon 2 at 420 nm is significantly higher than that of sequence 4.

[0057] This shows that only when molecular beacon 1 matches the target sequence 1 completely and molecular beacon 2 matches the target sequence 2 completely, an obvious ultraviolet absorption curve and absorption peak will be generated. Sequence 3 and sequence 4 have two mismatched bases respectively, and no obvious ultraviolet absorption curve and absorption peak are generated. That is, the molecular beacon provided by the present invention can have a high degree of matching with the target sequence, and only the target sequence that matches completely can porphyrin iron modify the molecular beacon, prompting its stem-loop structure to change, thereby forming a DNA enzyme that can oxidize ABTS to green ABTS+, and then generate an ultraviolet signal. This shows that the molecular beacon provided by the present invention has excellent recognition specificity for the target sequence.

[0058] 4. Quantitative detection

[0059] (1) Testing process

[0060] Sequence 2 with concentrations of 0.02 nM, 0.04 nM, 0.1 nM, 1 nM, 2 nM and 5 nM were mixed with 10 nM molecular beacon 2 in equal volumes in Tris-HCL buffer, heated in a water bath at 85°C for 5 min, cooled to room temperature for 30 min, and reacted in a water bath for 70 min to obtain a hybridization solution.

[0061] A 400 nM solution of sequence 6 was prepared with TE buffer, heated in a 90°C water bath for 10 min, and then annealed in an ice bath for 10 min to prevent sequence 6 from self-aggregation and convert it into a straight chain.

[0062] Take 100 μL of a mixture of equal volumes of hybridization solution and sequence 6 solution, add 200 μL 2×HEPES, 90 μL porphyrin iron culture medium (containing 25 mM HEPES, 200 mM sodium chloride, 20 mM potassium chloride, pH 8.0), 5 μL KCL solution and 5 μL DMSO, and oscillate in a 30°C water bath for 60 minutes to form DNA enzyme, and sequence 1 can be detected by colorimetry.

[0063] UV detection: Take 1mL of DNA enzyme solution and place it in a 1cm optical path quartz cuvette, add 15μL of 1.46mM ABTS solution and mix well as the base solution, scan the baseline to deduct the background signal, then add 9μL of 1.22mM hydrogen peroxide solution, mix well, and then measure its UV kinetic absorption curve. The wavelength range is 400-500nm, the scanning speed is 1200nm / s, and the UV scanning detection is 10min.

[0064] (2) Test results

[0065] like Figure 5 As shown, the intensity of UV absorbance gradually increases with the increase of concentration of sequence 2 and has a peak at 420 nm.

[0066] like Figure 6 and 7 As shown, the UV detection wavelength was fixed at 420nm to detect the absorbance value, and the 420nm absorbance value obtained from the reaction system without adding sequence 1 was used as a blank control to detect the relationship between the 420nm absorbance value difference and the concentration of sequence 1. The results showed that the logarithm of the concentration of sequence 1 had a good linear relationship with the 420nm absorbance value, and the detection limit was 0.02nM.

[0067] 5. Evaluation of hybrid specificity

[0068] Molecular beacon 1 was used to hybridize with 5nM sequence 1, sequence 2, sequence 3, sequence 4 and sequence 5, and then formed DNA enzyme with sequence 6, and the absorbance value was 420nM by ultraviolet detection. In addition, a mixed solution I of 5nM sequence 2 and 0.04nM sequence 1 was used to hybridize with molecular beacon 1 and then formed DNA enzyme with sequence 6, and the absorbance value was 420nM by ultraviolet detection. A mixed solution II of 5nM sequence 1 and 0.04nM sequence 2 was used to hybridize with molecular beacon 2 and then formed DNA enzyme with sequence 6, and the absorbance value was 420nM by ultraviolet detection. The reaction system was the same as above.

[0069] like Figure 8 As shown, only the detection value of 420nM of sequence 1 is the largest, and the absorbance values ​​of other sequences are slightly different from those of the control group. This shows that the porphyrin iron modified molecular beacon provided by the present invention has high specificity for detecting the mutation site.

[0070] 6. Amplification of target sequence containing chr6:31880443:T>G

[0071] The primers and probes shown in Table 2 were synthesized. Among them, F is the upstream primer that matches the target sequence of chr6:31880443:T. Fm is the downstream primer that matches the target sequence of chr6:31880443:G. R is the downstream primer. The primers and target sequences were prepared with double distilled water to 20 μM and kept at 4°C for use.

[0072] Table 2

[0073]

[0074]

[0075] The amplification system was (20 μL): 2 μL target sequence, 0.4 μL F, 0.4 μL R, 0.4 μL P, 4 μL 5× buffer, 2 μL 10× buffer, 2 μL dNTP, 0.2 μL DNA polymerase and the remaining double distilled water, with target sequence 2 as the control. Similarly, Fm and R were used as primer pairs to amplify target sequence 2, with target sequence 1 as the control. The amplification program was: preheating stage: 50°C 2min, 95°C 10min; reaction stage (40 cycles): 95°C 15sec; 60°C 35sec. The PCR product was stored at 4°C for subsequent agarose gel electrophoresis verification experiments. The gel concentration used in the electrophoresis was 2.0%, the operating voltage was 100V, and the time was 60 minutes. The instrument for the electrophoresis experiment was a vertical electrophoresis tank (bio-rad, USA).

[0076] like Fig. 9 As shown, F and R were used as primer pairs to amplify target sequence 2 (lane 1) and target sequence 1 (lane 2). As a result, amplified products were also detected in target sequence 2, indicating that F and R were not specific enough to amplify target sequence 1. Fm and R were used as primer pairs to amplify target sequence 2 (lane 3) and target sequence 4 (lane 4). As a result, amplified products were also detected in target sequence 4, indicating that Fm and R were not specific enough to amplify target sequence 2.

[0077] 7. Testing of clinical samples

[0078] (1) Clinical samples

[0079] 3 mL of peripheral venous blood was collected from patients with hyperuricemia who had been taking allopurinol for a long time and had severe adverse reactions such as high fever and severe mucosal erosion after taking the drug. 300 μL of EDTA anticoagulated blood was added and the blood genomic DNA extraction reagent (100 rxns, model 70423-100, BeaverBeads TM ) to extract genomic DNA as a positive sample (containing approximately 100 ng / mL).

[0080] Negative samples: 3 mL of peripheral venous blood from patients with hyperuricemia who had been taking allopurinol for a long time and had no obvious allergic reaction was added with 300 μL of ETA anticoagulated blood and the blood genomic DNA was extracted using a blood genomic DNA extraction reagent (100 rxns, model 70423-100, BeaverBeads TM) was used to extract genomic DNA as a negative sample (containing approximately 100 ng / mL).

[0081] (2) Detection

[0082] F and R were used as primer pairs to amplify positive samples and negative samples, and Fm and R were used as primer pairs to amplify positive samples and negative samples. The PCR amplification system and amplification procedure were the same as above. The amplification products were detected by electrophoresis.

[0083] Molecular beacon 1 is used to detect positive samples and negative samples respectively, and molecular beacon 2 is used to detect positive samples and negative samples respectively. The hybridization process of the molecular beacon and the genomic DNA in the sample, the process of forming DNA enzyme and the ultraviolet detection process are the same as above.

[0084] First, use F and R as primer pairs to amplify positive samples and negative samples, and then use molecular beacon 1 to detect the amplification products of positive samples and negative samples, respectively. First, use Fm and R as primer pairs to amplify positive samples and negative samples, and then use molecular beacon 2 to detect the amplification products of positive samples and negative samples, respectively. No sample or amplification product was used as a control.

[0085] (3) Results

[0086] like Fig. 9 As shown, F and R were used as primer pairs to amplify positive samples (lane 5) and negative samples (lane 6), and Fm and R were used as primer pairs to amplify positive samples (lane 7) and negative samples (lane 8). Electrophoresis detection showed lighter bands, and it was impossible to effectively distinguish positive samples from negative samples.

[0087] like Fig.10 As shown, the 420nm ultraviolet absorbance of the negative sample (negative + beacon 1) directly detected by molecular beacon 1 is significantly higher than that of the positive sample (positive + beacon 1) directly detected by molecular beacon 1, and the absorbance value difference between the "positive + beacon 1" group and the control is not large. This shows that the molecular beacon 1 provided by the present invention can directly detect the venous blood of patients taking allopurinol and can effectively distinguish whether they have an allergic reaction.

[0088] like Fig.10 As shown, the 420nm ultraviolet absorbance of the negative sample (F / R+negative+beacon 1) amplified by the F / R primer pair detected by the molecular beacon 1 is significantly higher than that of the positive sample (F / R+positive+beacon 1) amplified by the F / R primer pair detected by the molecular beacon 1. This shows that the molecular beacon 1 provided by the present invention can be combined with PCR to detect the venous blood of patients taking allopurinol, and can effectively distinguish whether they have an allergic reaction.

[0089] like Fig.10As shown, the 420nm ultraviolet absorbance of the positive sample (positive + beacon 2) directly detected by molecular beacon 2 is significantly higher than that of the positive sample (negative + beacon 2) directly detected by molecular beacon 2, and the absorbance value of the "negative + beacon 2" group is not much different from that of the control. This shows that the molecular beacon 2 provided by the present invention can directly detect the venous blood of patients taking allopurinol and can effectively distinguish whether they have an allergic reaction.

[0090] like Fig.10 As shown, the 420nm ultraviolet absorbance of the positive sample (Fm / R+positive+beacon 2) amplified by the Fm / R primer pair detected by molecular beacon 2 is significantly higher than that of the negative sample (Fm / R+negative+beacon 2) amplified by the Fm / R primer pair detected by molecular beacon 2. This shows that the molecular beacon 2 provided by the present invention can be combined with PCR to detect the venous blood of patients taking allopurinol, and can effectively distinguish whether they have an allergic reaction.

[0091] The above description is only a preferred specific implementation manner of the present invention, but the protection scope of the present invention is not limited thereto. Any changes or substitutions that can be easily conceived by any technician familiar with the technical field within the technical scope disclosed by the present invention should be covered within the protection scope of the present invention.

Claims

1. An oligonucleotide composition for detecting allergic reactions to allopurinol, It is characterized in that include: Molecular Beacon 1: The two ends have amino groups, and the italicized part is the stem part of molecular beacon 1; Molecular Beacon 2: It has amino groups at both ends, and the italicized part is the stem part of molecular beacon 2; Sequence 6: 5'-GGGGTGGGTAGGGGTGGGTAGGGGTTGG-3'.

2. Kit for detecting allergic reactions to allopurinol. It is characterized in that The invention comprises the oligonucleotide composition according to claim 1.

3. The kit according to claim 2, further comprising include: F:GCATCAGCATTGCCTGGGGACTTT; Fm: GCATCAGCATTGCCTGGGGACTTG R: AAGTATTTCCTGGAGGACTTGGG.

4. The kit according to claim 2, It is characterized in that The invention comprises independently packaged 40-150nM molecular beacon 1 solution, 40-150nM molecular beacon 2 solution, 50-200nM sequence 6 solution, 1-2mM ABTS solution and 1-2mM hydrogen peroxide solution.

5. The kit according to claim 4, It is characterized in that Also included are independently packaged 10-50 nM F solution, 10-50 nM Fm solution and 10-50 nM R solution.

6. Methods for detecting allergic reactions to allopurinol. It is characterized in that include: Reacting the DNA of the sample to be tested with the molecular beacon 1 or the molecular beacon 2 to obtain a hybridization solution; The hybridization solution is mixed with the sequence 6 solution to form a DNA enzyme solution; ABTS solution and hydrogen peroxide solution were added to the DNA enzyme solution, and the ultraviolet absorption value at 420 nm was detected.

7. The method according to claim 6, It is characterized in that include: A solution containing 40 nM molecular beacon 1 or molecular beacon 2 and 20 nM DNA of the sample to be tested was prepared with Tris-HCl solution, heated in a water bath at 85°C for 5 min, cooled to room temperature for 30 min, and reacted in a water bath for 65 min; A 160 nM solution of sequence 6 was prepared in TE buffer, heated in a 90°C water bath for 10 min, and then annealed in an ice bath for 10 min to prevent sequence 6 from self-aggregation and convert it into a straight chain; Take 100 μL of the hybridization solution and the mixture of equal volumes of sequence 6 solution, add 200 μL 2×HEPES, 90 μL porphyrin iron culture solution, 5 μL KCL solution and 5 μL DMSO, shake evenly and transfer to a 30°C water bath shaker in the dark for 60 minutes to form a DNase solution; Take 1mL of DNA enzyme solution and place it in a 1cm optical path quartz cuvette, add 15μL of 1.46mM ABTS solution and mix well as the base solution, scan the baseline to subtract the background signal, then add 9μL of 1.22mM hydrogen peroxide solution, mix well, and detect the ultraviolet absorption value at 420nm.

8. The method according to claim 6 or 7, It is characterized in that Also includes: First, the DNA of the sample to be tested is amplified by PCR. The amplification system is (20 μL): 2 μL DNA of the sample to be tested, 0.4 μL F or Fm, 0.4 μL R, 0.4 μL P, 4 μL 5× buffer, 2 μL 10× buffer, 2 μL dNTP, 0.2 μL DNA polymerase and the balance double distilled water; The amplification program was as follows: preheating phase: 50°C for 2 min, 95°C for 10 min; reaction phase (40 cycles): 95°C for 15 sec; 60°C for 35 sec.

9. Use of the oligonucleotide composition according to claim 1 or the kit according to any one of claims 2 to 5 in the preparation of a reagent for detecting an allergic reaction to allopurinol.

Citation Information

Patent Citations

  • PCR (polymerase chain reaction) nucleic acid detection method

    CN102071251A

  • Oligonucleotide probe, and method for detecting target molecule through using it

    CN102827836A